Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Yingda L. Xie, Veronique de Jager, Ray Y. Chen, Lori E. Dodd, Praveen Paripati, Laura E. Via, Dean Follmann, Jing Wang, Keith Lumbard, Saher Lahouar, Stephanus T. Malherbe, Jenna Andrews, Xiang Yu, Lisa C. Goldfeder, Ying Cai, Kriti Arora, André G. Loxton, Naadira Vanker, Michael Duvenhage, Jill Winter, Taeksun Song, Gerhard Walzl, Andreas H. Diacon, Clifton E. Barry
Abstract
F]FDG-PET/CT imaging may be useful for measuring the activity of single drugs and drug combinations during evaluation of potential new TB drug regimens before phase 3 trials.
Topics & Concepts
MedicineTuberculosisPet imagingDrugNuclear medicinePositron emission tomographyRadiologyPharmacologyPathologyTuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisDiagnosis and treatment of tuberculosis